The role of GATA2 in lethal prostate cancer aggressiveness

Veronica Rodriguez-Bravo, Marc Carceles-Cordon, Yujin Hoshida, Carlos Cordon-Cardo, Matthew D. Galsky, Josep Domingo-Domenech

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Advanced prostate cancer is a classic example of the intractability and consequent lethality that characterizes metastatic carcinomas. Novel treatments have improved the survival of men with prostate cancer; however, advanced prostate cancer invariably becomes resistant to these therapies and ultimately progresses to a lethal metastatic stage. Consequently, detailed knowledge of the molecular mechanisms that control prostate cancer cell survival and progression towards this lethal stage of disease will benefit the development of new therapeutics. The transcription factor endothelial transcription factor GATA-2 (GATA2) has been reported to have a key role in driving prostate cancer aggressiveness. In addition to being a pioneer transcription factor that increases androgen receptor (AR) binding and activity, GATA2 regulates a core subset of clinically relevant genes in an AR-independent manner. Functionally, GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 has a multifaceted function in prostate cancer aggressiveness and is a highly attractive target in the development of novel treatments against lethal prostate cancer.

Original languageEnglish (US)
Pages (from-to)38-48
Number of pages11
JournalNature Reviews Urology
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Androgen Receptors
GATA2 Transcription Factor
Transcription Factors
Therapeutics
Prostate Cancer, Hereditary, 7
Cell Survival
Carcinoma
Survival
Genes

ASJC Scopus subject areas

  • Urology

Cite this

Rodriguez-Bravo, V., Carceles-Cordon, M., Hoshida, Y., Cordon-Cardo, C., Galsky, M. D., & Domingo-Domenech, J. (2017). The role of GATA2 in lethal prostate cancer aggressiveness. Nature Reviews Urology, 14(1), 38-48. https://doi.org/10.1038/nrurol.2016.225

The role of GATA2 in lethal prostate cancer aggressiveness. / Rodriguez-Bravo, Veronica; Carceles-Cordon, Marc; Hoshida, Yujin; Cordon-Cardo, Carlos; Galsky, Matthew D.; Domingo-Domenech, Josep.

In: Nature Reviews Urology, Vol. 14, No. 1, 01.01.2017, p. 38-48.

Research output: Contribution to journalReview article

Rodriguez-Bravo, V, Carceles-Cordon, M, Hoshida, Y, Cordon-Cardo, C, Galsky, MD & Domingo-Domenech, J 2017, 'The role of GATA2 in lethal prostate cancer aggressiveness', Nature Reviews Urology, vol. 14, no. 1, pp. 38-48. https://doi.org/10.1038/nrurol.2016.225
Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J. The role of GATA2 in lethal prostate cancer aggressiveness. Nature Reviews Urology. 2017 Jan 1;14(1):38-48. https://doi.org/10.1038/nrurol.2016.225
Rodriguez-Bravo, Veronica ; Carceles-Cordon, Marc ; Hoshida, Yujin ; Cordon-Cardo, Carlos ; Galsky, Matthew D. ; Domingo-Domenech, Josep. / The role of GATA2 in lethal prostate cancer aggressiveness. In: Nature Reviews Urology. 2017 ; Vol. 14, No. 1. pp. 38-48.
@article{1b87f537831243d0a999ac375904949b,
title = "The role of GATA2 in lethal prostate cancer aggressiveness",
abstract = "Advanced prostate cancer is a classic example of the intractability and consequent lethality that characterizes metastatic carcinomas. Novel treatments have improved the survival of men with prostate cancer; however, advanced prostate cancer invariably becomes resistant to these therapies and ultimately progresses to a lethal metastatic stage. Consequently, detailed knowledge of the molecular mechanisms that control prostate cancer cell survival and progression towards this lethal stage of disease will benefit the development of new therapeutics. The transcription factor endothelial transcription factor GATA-2 (GATA2) has been reported to have a key role in driving prostate cancer aggressiveness. In addition to being a pioneer transcription factor that increases androgen receptor (AR) binding and activity, GATA2 regulates a core subset of clinically relevant genes in an AR-independent manner. Functionally, GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 has a multifaceted function in prostate cancer aggressiveness and is a highly attractive target in the development of novel treatments against lethal prostate cancer.",
author = "Veronica Rodriguez-Bravo and Marc Carceles-Cordon and Yujin Hoshida and Carlos Cordon-Cardo and Galsky, {Matthew D.} and Josep Domingo-Domenech",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/nrurol.2016.225",
language = "English (US)",
volume = "14",
pages = "38--48",
journal = "Nature reviews. Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The role of GATA2 in lethal prostate cancer aggressiveness

AU - Rodriguez-Bravo, Veronica

AU - Carceles-Cordon, Marc

AU - Hoshida, Yujin

AU - Cordon-Cardo, Carlos

AU - Galsky, Matthew D.

AU - Domingo-Domenech, Josep

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Advanced prostate cancer is a classic example of the intractability and consequent lethality that characterizes metastatic carcinomas. Novel treatments have improved the survival of men with prostate cancer; however, advanced prostate cancer invariably becomes resistant to these therapies and ultimately progresses to a lethal metastatic stage. Consequently, detailed knowledge of the molecular mechanisms that control prostate cancer cell survival and progression towards this lethal stage of disease will benefit the development of new therapeutics. The transcription factor endothelial transcription factor GATA-2 (GATA2) has been reported to have a key role in driving prostate cancer aggressiveness. In addition to being a pioneer transcription factor that increases androgen receptor (AR) binding and activity, GATA2 regulates a core subset of clinically relevant genes in an AR-independent manner. Functionally, GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 has a multifaceted function in prostate cancer aggressiveness and is a highly attractive target in the development of novel treatments against lethal prostate cancer.

AB - Advanced prostate cancer is a classic example of the intractability and consequent lethality that characterizes metastatic carcinomas. Novel treatments have improved the survival of men with prostate cancer; however, advanced prostate cancer invariably becomes resistant to these therapies and ultimately progresses to a lethal metastatic stage. Consequently, detailed knowledge of the molecular mechanisms that control prostate cancer cell survival and progression towards this lethal stage of disease will benefit the development of new therapeutics. The transcription factor endothelial transcription factor GATA-2 (GATA2) has been reported to have a key role in driving prostate cancer aggressiveness. In addition to being a pioneer transcription factor that increases androgen receptor (AR) binding and activity, GATA2 regulates a core subset of clinically relevant genes in an AR-independent manner. Functionally, GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 has a multifaceted function in prostate cancer aggressiveness and is a highly attractive target in the development of novel treatments against lethal prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84996636861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996636861&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2016.225

DO - 10.1038/nrurol.2016.225

M3 - Review article

C2 - 27872477

AN - SCOPUS:84996636861

VL - 14

SP - 38

EP - 48

JO - Nature reviews. Urology

JF - Nature reviews. Urology

SN - 1759-4812

IS - 1

ER -